CVS Caremark, one of the nation’s largest pharmacy benefit managers, has reversed course on its exclusion of Eli Lilly’s Zepbound weight loss injection and announced plans to include the company’s investigational oral obesity medication orforglipron in its drug formularies. The decision marks a significant expansion of coverage for weight management therapeutics amid growing demand for GLP-1 receptor agonist medications across the United States healthcare system.
The pharmacy benefit manager’s policy reversal comes after initially removing Zepbound from its standard formularies earlier this year, a move that would have affected millions of commercially insured patients. CVS Caremark manages prescription drug benefits for approximately 90 million Americans through employer-sponsored health plans, making its formulary decisions critical for determining patient access to medications. The U.S. Food and Drug Administration approved Zepbound, which contains the active ingredient tirzepatide, for chronic weight management in November 2023 for adults with obesity or overweight conditions with weight-related comorbidities.
Industry analysts estimate the global weight loss drug market could reach $100 billion annually by 2030, driven by medications like Zepbound and competing products from Novo Nordisk. Eli Lilly reported that Zepbound generated $1.26 billion in revenue during the fourth quarter of 2024, demonstrating substantial commercial uptake since its market introduction. The medication works by activating both GIP and GLP-1 receptors, which regulate blood sugar levels and appetite, leading to average weight loss of approximately 22.5 percent in clinical trials over 72 weeks.
The inclusion of orforglipron represents a strategic addition to CVS Caremark’s obesity treatment portfolio. This experimental oral medication, currently in phase three clinical development, offers a potential alternative to injectable weight loss therapies that require weekly administration. Early clinical data presented at medical conferences showed that orforglipron produced weight reductions of up to 14.7 percent at the highest doses tested after 36 weeks of treatment. If approved by regulatory authorities, orforglipron would become one of the first oral GLP-1 medications specifically indicated for obesity management.
Pharmacy benefit managers have faced increasing scrutiny regarding their formulary management practices, particularly for high-cost specialty medications. The Centers for Medicare and Medicaid Services has implemented new transparency requirements for PBMs, mandating disclosure of rebate arrangements and formulary placement criteria. These regulatory changes aim to ensure that coverage decisions prioritize patient outcomes rather than manufacturer rebates or competitive exclusion strategies.
Employer health plans continue grappling with the financial implications of covering weight loss medications, which typically cost between $900 and $1,300 per month before insurance. Approximately 42 percent of the U.S. adult population meets clinical criteria for obesity, creating potential utilization that could strain pharmacy budgets. Many employers have implemented prior authorization requirements, quantity limits, or lifestyle modification prerequisites before approving coverage for anti-obesity medications.
Eli Lilly’s expanded presence on CVS formularies strengthens its competitive position against Novo Nordisk’s Wegovy, which uses the same active ingredient as the diabetes medication Ozempic. Both pharmaceutical companies have invested billions in manufacturing capacity expansion to meet surging demand, though periodic supply constraints have affected product availability throughout 2024. Eli Lilly announced $18 billion in capital investments to increase production capacity for tirzepatide-based products at facilities in Indiana, North Carolina, and Ireland.
Healthcare policy experts note that broader insurance coverage for obesity medications could yield long-term cost savings by reducing complications from obesity-related conditions including type 2 diabetes, cardiovascular disease, and certain cancers. Research published in medical economics journals suggests that every dollar spent on obesity treatment could generate $3 to $4 in avoided healthcare costs over a ten-year horizon. However, budget impact analyses remain challenging due to uncertainty about long-term medication adherence rates and the durability of weight loss outcomes after treatment discontinuation.
The formulary modifications will take effect during the next plan year for most CVS Caremark clients, though specific coverage terms including copayment amounts and utilization management criteria will vary based on individual employer plan designs. Patients currently prescribed Zepbound should verify their specific coverage status with their insurance providers as implementation timelines differ across markets and customer segments.